Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Documents

C0450000

Carbamazepine

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

5H-Dibenz[b,f]azepine-5-carboxamide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C15H12N2O
Numéro CAS:
Poids moléculaire :
236.27
Numéro MDL:
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

carbamazepine

Fabricant/nom de marque

EDQM

Pf

191-192 °C (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

NC(=O)N1c2ccccc2C=Cc3ccccc13

InChI

1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)

Clé InChI

FFGPTBGBLSHEPO-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Carbamazepine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Anticonvulsant; ligand for the GABAA receptor benzodiazepine modulatory site. Sodium channel inhibitor.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Pictogrammes

Health hazardExclamation mark

Mention d'avertissement

Danger

Mentions de danger

Classification des risques

Acute Tox. 4 Oral - Repr. 1A - Resp. Sens. 1 - Skin Sens. 1A - STOT SE 3

Organes cibles

Central nervous system

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Anna Jurado et al.
Chemosphere, 115, 47-53 (2014-02-25)
This paper deals with urban groundwater contaminated with carbamazepine (CBZ) and five of its human metabolites in Barcelona. Groundwater samples were accordingly collected in the aquifers of Poble Sec and Besòs River Delta. Higher concentrations and more compounds were found
Philip J Wiffen et al.
The Cochrane database of systematic reviews, (1)(1), CD005451-CD005451 (2011-01-21)
Carbamazepine is used to treat chronic neuropathic pain. Evaluation of analgesic efficacy and adverse effects of carbamazepine for acute and chronic pain management (except headaches). Randomised controlled trials (RCTs) of carbamazepine in acute, chronic or cancer pain were identified, searching
Wimonchat Tangamornsuksan et al.
JAMA dermatology, 149(9), 1025-1032 (2013-07-26)
The US Food and Drug Administration recommends screening for the HLA-B*1502 allele before initiation of carbamazepine therapy in patients of Asian ancestry, but there remains unclear evidence of a relationship between HLA-B*1502 and Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis
Ursula Amstutz et al.
Epilepsia, 55(4), 496-506 (2014-03-07)
To systematically review evidence on genetic risk factors for carbamazepine (CBZ)-induced hypersensitivity reactions (HSRs) and provide practice recommendations addressing the key questions: (1) Should genetic testing for HLA-B*15:02 and HLA-A*31:01 be performed in patients with an indication for CBZ therapy
Sandeep Grover et al.
Pharmacogenetics and genomics, 24(2), 94-112 (2013-12-18)
A considerable heterogeneity exists in the literature on the role of different HLA alleles in carbamazepine (CBZ)-induced cutaneous adverse drug reactions (cADRs) of varying severity among diverse ethnic groups. The aim of the present study was to understand and summarize

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique